Heidelberg, October 9, 2006 – After successful completion of the capital increase in connection with the acquisition of SYGNIS Bioscience GmbH & Co. KG, the Supervisory Board of LION bioscience AG today appointed Dr. Alfred Bach to the Management Board with effect of October 10, 2006. Up to now Dr. Alfred Bach was CEO of Axaron Bioscience AG, a drug developing company in the field of CNS (central nervous system). Dr. Alfred Bach will serve as CEO, and Peter Willinger as CFO of LION bioscience AG. The acquisition of all the shares in SYGNIS Bioscience GmbH & Co. KG, as announced in July 2006, was now successfully completed with registration in the commercial register. Following the acquisition of SYGNIS Bioscience GmbH & Co. KG, the share capital of LION bioscience AG was increased by Euro 7.807.535 from Euro 19.870.175 to Euro 27.677.710. Lion bioscience AG will present the next steps for future development on the annual shareholders’ meeting for fiscal year 2005/2006 on November 28, 2006 in Eppelheim.
